IDEXX Laboratories, Inc. $IDXX Shares Sold by Quantitative Investment Management LLC

Quantitative Investment Management LLC reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.8% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 3,148 shares of the company’s stock after selling 1,214 shares during the period. Quantitative Investment Management LLC’s holdings in IDEXX Laboratories were worth $1,657,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Harbour Investments Inc. boosted its stake in IDEXX Laboratories by 13.3% in the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after acquiring an additional 16 shares during the period. Pinnacle Associates Ltd. lifted its holdings in shares of IDEXX Laboratories by 1.5% in the 4th quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock worth $830,000 after purchasing an additional 18 shares during the last quarter. Triad Wealth Partners LLC lifted its holdings in shares of IDEXX Laboratories by 3.1% in the 1st quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock worth $337,000 after purchasing an additional 18 shares during the last quarter. Advisory Services Network LLC boosted its position in IDEXX Laboratories by 2.5% during the 4th quarter. Advisory Services Network LLC now owns 752 shares of the company’s stock valued at $509,000 after purchasing an additional 18 shares during the period. Finally, KCM Investment Advisors LLC grew its stake in IDEXX Laboratories by 5.3% during the 4th quarter. KCM Investment Advisors LLC now owns 377 shares of the company’s stock worth $255,000 after buying an additional 19 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $556.69 on Tuesday. IDEXX Laboratories, Inc. has a 1 year low of $518.55 and a 1 year high of $769.98. The firm has a market cap of $43.86 billion, a P/E ratio of 39.15, a PEG ratio of 2.96 and a beta of 1.54. The stock has a fifty day moving average price of $559.23 and a two-hundred day moving average price of $572.70. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on IDXX shares. UBS Group boosted their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Citigroup boosted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Barclays cut their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Finally, Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $747.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.